FindTrial
Sign In

Therapeutic effects of tanshinone IIA towards early renal damage in patients with type 2 diabetes

Therapeutic effects of tanshinone IIA towards early renal damage in patients with type 2 diabetes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TQR-14005142
Enrollment
Unknown
Registered
2014-09-21
Start date
2014-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early renal damage in type 2 diabetes

Interventions

trial:0.75 mg/kg/day intravenous Tanshinone IIA +standard Western therapy involving oral hypoglycemic drugs
Control:standard Western therapy involving oral hypoglycemic drugs

Sponsors

Cadre's Ward, 281 hospital of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes; urinary albumin excretion of 30-300mg/24h; continued Western therapy involving oral hypoglycemic drugs; Men and women aged 30-65 years old.

Exclusion criteria

Exclusion criteria: Chronic inflammatory diseases, acute or chronic kidney disease, hyperlipemia, hypertension, hyperuricemia, cardiac and cerebrovascular diseases, cancer, tobacco and alcohol hobbies.

Design outcomes

Primary

MeasureTime frame
microalbuminuria;serum beta 2 microglobulin;urine beta 2 microglobulin;serum cystatin C;—

Secondary

MeasureTime frame
glycated hemoglobin A1c (HbA1c);—

Countries

China

Contacts

Public ContactHan Feng
wdyxzh2009@163.com+86 18830452920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026